King's Health Partners (KHP) Experimental Cancer Medicine Centre (ECMC) combines research activity within King’s College London with clinical expertise in the Comprehensive Cancer Centre based at the College’s two partner NHS Foundation Trusts, Guy’s & St Thomas’, and King’s College Hospital.
Areas of expertise include cellular and molecular immunotherapy, imaging (allied to the Comprehensive Cancer Imaging Centre, a joint centre with UCL), and the development of devices for cancer surgery. KHP ECMC is hosted within the Guy's Clinical Research Facility, which is MHRA-accredited as a Phase 1 unit. Cell therapy and protein GMP production facilities are located at Guy's and King's College Hospital Campuses. Translational laboratory facilities are provided within the new £160m Guy's Cancer Centre opened in 2016.
Aims of the KHP ECMC include:
- delivery of new interventions in the clinic in appropriately stratified populations
- clinical development of immuno-therapeutics discovered in-house
- optimisation of pharmacodynamic endpoints used in clinical development of novel therapies
For more information about the ECMC click here.